0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover207.73%IV-92.31%PremiumDec 20, 2024Expiry Date7.20Intrinsic Value100Multiplier30DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7861Delta0.0636Gamma1.03Leverage Ratio-0.0211Theta-0.0085Rho-0.81Eff Leverage0.0066Vega
Foghorn Therapeutics Stock Discussion
loading...
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet